ERBB2 and breast neoplasm: Mutations at NCOR1 were associated with detrimental outcome in all breast tumors (HR:0.63, CI: 0.56–0.7; log rank p = 0), luminal B (HR:0.65, CI: 0.54–0.79; log rank p = 1.2e-05), basal (HR:0.58, CI: 0.45–0.76; log rank p = 3.3e-05) and HER2 positive tumors (HR:0.62, CI: 0.43–0.90; log rank p = 0.012) (Fig 2A, 2B, 2C and 2D, respectively).